Philips, Celsion team on MR-guided high intensity US cancer treatment
The FDA has provided clearance to initiate a clinical study supporting a joint development program for Celsion’s ThermoDox cancer treatment combined with Philips’ Sonalleve MR-guided high intensity focused ultrasound (MR-HIFU).
ThermoDox, from Lawrenceville, N.J.-based biotech company Celsion, is a heat-activated liposomal encapsulation of doxorubicin being evaluated in multiple clinical trials, with the lead program focused on liver cancer. The current joint program with Philips would investigate how effective ThermoDox combined with MR-HIFU is at relieving pain in patients with bone metastases caused by lung, prostate or breast cancers.
The two companies expect to initiate a Phase 2 study in this indication in the second half of 2012.
ThermoDox, from Lawrenceville, N.J.-based biotech company Celsion, is a heat-activated liposomal encapsulation of doxorubicin being evaluated in multiple clinical trials, with the lead program focused on liver cancer. The current joint program with Philips would investigate how effective ThermoDox combined with MR-HIFU is at relieving pain in patients with bone metastases caused by lung, prostate or breast cancers.
The two companies expect to initiate a Phase 2 study in this indication in the second half of 2012.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.